clinical trial · NCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Amgen·phase3·recruiting·n = 60
Active Juvenile Psoriatic ArthritisApremilastPlacebo
brief summary
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
started
Mar 17, 2022
primary completion
Mar 21, 2028
completion
Dec 29, 2028
last updated
Apr 20, 2026
official title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol